RESEARCH AND EDUCATION DISCLAIMER
This article summarizes published scientific research for educational purposes only. Level Up Peptides products are intended exclusively for laboratory research by qualified researchers and are not for human or veterinary use. Discussion of published animal or human studies does not recommend those uses or establish the safety or effectiveness of any product sold on this website. This article does not provide medical advice, dosing guidance, or administration instructions.
SUMMARY
CagriSema is the combination of cagrilintide and semaglutide studied in clinical development. Published randomized trials have evaluated body weight, blood-glucose measures, and adverse events in adults with and without type 2 diabetes. The findings support activity of the combination under the conditions studied, but the size of an effect depends on the population and analysis. Clinical formulations are not interchangeable with separately supplied research materials or mixtures. [1–3]
WHAT IS CAGRISEMA?
CagriSema combines two distinct molecules: semaglutide, a GLP-1 receptor agonist, and cagrilintide, a long-acting amylin analogue. An agonist activates a receptor, allowing researchers to investigate the biological responses associated with that signaling pathway. This is a combination strategy, rather than a single peptide that should be described as both ingredients at once. [1]
Its rationale is to investigate complementary pathways involved in metabolic regulation. A plausible rationale is not enough to establish the combination's effects; direct comparison with the individual components and an appropriate control is needed.
WHAT DID THE EARLY TYPE 2 DIABETES TRIAL SHOW?
A 2023 phase 2 trial randomized 92 adults with type 2 diabetes to the combination, semaglutide, or cagrilintide for 32 weeks. The primary outcome was change in HbA1c, a measure of longer-term blood-glucose control. [1]
The combination reduced HbA1c more than cagrilintide, but its difference from semaglutide did not reach statistical significance. Body-weight reduction, a secondary outcome, was greater with the combination than with either component. Gastrointestinal adverse events were the most common and were generally mild or moderate. [1]
These findings show why the outcome must be named. A stronger result for body weight does not establish superiority on every measure of metabolic health.
WHAT DID REDEFINE 1 FIND IN ADULTS WITHOUT DIABETES?
The 2025 REDEFINE 1 report included 3,417 adults with obesity, or overweight with an associated complication, without diabetes. Participants were assigned to the combination, either individual component, or placebo; all groups received lifestyle intervention. [2]
At 68 weeks, estimated average body-weight change was a reduction of 20.4% with the combination and 3.0% with placebo. These estimates considered outcomes regardless of treatment discontinuation. They describe group averages under trial conditions, not an expected result for every participant. [2]
Gastrointestinal adverse events occurred in 79.6% of combination participants and 39.9% of placebo participants. Most were temporary and mild to moderate, but the frequency remains relevant when evaluating the findings. [2]
WHAT DID REDEFINE 2 FIND IN TYPE 2 DIABETES?
REDEFINE 2 randomized 1,206 adults with type 2 diabetes and overweight or obesity to CagriSema or placebo for 68 weeks, alongside lifestyle intervention. Estimated average body-weight reduction was 13.7% with the combination and 3.4% with placebo. [3]
This was a different study population from REDEFINE 1. The different percentages should not be interpreted as a controlled comparison between people with and without diabetes. Eligibility, baseline characteristics, background medications, and other factors can influence outcomes.
REDEFINE 2 did not include separate cagrilintide-only and semaglutide-only groups. It therefore demonstrates a comparison with placebo, rather than isolating the contribution of each component. [3]
HOW SHOULD PERCENTAGES FROM DIFFERENT REPORTS BE READ?
A study can estimate outcomes under different assumptions, including whether treatment continues or is discontinued. Follow-up duration and missing measurements also affect interpretation. A larger number in a headline may reflect a different question being analyzed rather than a contradictory result.
The trial name, population, time point, and analysis should therefore accompany any numerical claim. Likewise, a result for the combination should not be presented as a result for cagrilintide alone or semaglutide alone.
WHAT REMAINS UNCERTAIN?
These studies do not resolve every question about durability, uncommon adverse events, or longer-term clinical outcomes. Body-weight change also cannot automatically be translated into claims about longevity or cardiovascular protection without studies measuring those outcomes for the combination.
Finally, the published results concern the formulations and manufacturing controls used in the clinical program. They do not verify the identity, purity, stability, compatibility, or performance of a separately prepared research mixture. The evidence should be read as clinical-development research, not as instructions or validation for personal use.
REFERENCES
Some study titles below are shortened for readability; each link identifies the original publication.
[1] Frias JP, Deenadayalan S, Erichsen L, et al. Coadministered cagrilintide and semaglutide in type 2 diabetes: a randomized phase 2 trial. The Lancet. 2023;402:720–730.
https://doi.org/10.1016/S0140-6736(23)01163-7
[2] Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2025;393:635–647.
https://doi.org/10.1056/NEJMoa2502081
[3] Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. New England Journal of Medicine. 2025;393:648–659.
https://doi.org/10.1056/NEJMoa2502082